TuHURA Biosciences (NASDAQ:HURA – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $10.00 price target on the stock. HC Wainwright‘s target price indicates a potential upside of 391.16% from the company’s current price.
HURA has been the subject of a number of other research reports. Citizens Jmp reaffirmed a “market outperform” rating and issued a $9.00 price target on shares of TuHURA Biosciences in a report on Tuesday, August 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, October 15th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.00.
Check Out Our Latest Analysis on TuHURA Biosciences
TuHURA Biosciences Stock Performance
TuHURA Biosciences (NASDAQ:HURA – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. Sell-side analysts anticipate that TuHURA Biosciences will post -0.55 EPS for the current fiscal year.
Hedge Funds Weigh In On TuHURA Biosciences
A number of hedge funds have recently made changes to their positions in HURA. Two Sigma Securities LLC purchased a new position in TuHURA Biosciences in the second quarter worth approximately $33,000. Merck & Co. Inc. grew its position in TuHURA Biosciences by 39.4% in the first quarter. Merck & Co. Inc. now owns 19,445 shares of the company’s stock worth $35,000 after acquiring an additional 5,495 shares during the period. Sanctuary Advisors LLC purchased a new position in TuHURA Biosciences in the second quarter worth approximately $49,000. Deutsche Bank AG purchased a new position in TuHURA Biosciences in the second quarter worth approximately $52,000. Finally, PFG Investments LLC grew its position in TuHURA Biosciences by 39.4% in the first quarter. PFG Investments LLC now owns 32,630 shares of the company’s stock worth $58,000 after acquiring an additional 9,219 shares during the period. Institutional investors and hedge funds own 0.62% of the company’s stock.
About TuHURA Biosciences
TuHURA Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies.
TuHURA’s lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments.
Featured Stories
- Five stocks we like better than TuHURA Biosciences
- Sherwin-Williams Remains Evergreen in a Frozen Housing Market
- Palantir’s Q3 Bar Is Higher Than It Looks: 3 Numbers to Watch
- Johnson Controls Beats the Heat in AI Data Centers
- 3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
